MSH2 and mismatch repair cancer syndrome 1: The tumor was hypermutated (56.7 somatic mutations per Mb, Table 2), showed the mutation signature of mismatch repair deficiency (Alexandrov et al., 2013), and had MSH‐2 and MSH‐6 protein losses as determined by immunohistochemistry (Fig. 4, Tables 2 and S1).